Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022

The market for Type 2 Diabetes Mellitus (T2DM) is expected to grow from $1.7 billion in 2015 to $2.7 billion in 2022, at a Compound Annual Growth Rate (CAGR) of 7.1%. This growth will be driven by the rapidly expanding prevalence population, due to increasingly aging populations and sedentary lifestyles, as well as increases in the diagnosis and treatment rates, due to rising disease awareness among the public. The increased uptake of recently approved and emerging branded therapeutics, in favor of lower-cost generic products, will also propel market growth.

The T2DM market contains a wide range of drugs that are used to treat patients at different points in the treatment algorithm. The drug therapies are broadly classified into insulin therapies and non-insulin agents. The patient share for these categories varies from country to country. The market landscape is densely populated, with a number of drugs competing for different market segments across multiple lines of therapy. The first-line therapy is usually metformin, a generic drug administered in more than 50% of T2DM cases. However, it is often unable to bring the disease under control.

GBI Research’s latest report Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth, provides analysis of the Type 2 Diabetes Mellitus market across South-East Asia, which includes, South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam and Indonesia. It includes annualized market data from 2015 and forecast to 2022.

The report will help understand:

  • What are the competitive advantages of the existing novel drugs and Which classes are most prominent within the pipeline?
  • Is there a strong potential for the pipeline to address unmet needs within the T2DM market?
  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
  • Which markets make the most significant contribution to the current market size?
  • Will new market entrants lead to substantial changes in annual therapy costs?
  • How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?
  • Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?

$4,995 (Single User License)
Published: Aug -16
Publisher: GBI Research
Report Format: electronic pdf

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s